Human embryonic stem cell derived-mesenchymal stem cells: an alternative mesenchymal stem cell source for regenerative medicine therapy

被引：1
作者：
Gadkari, Rishali [1 ]
Zhao, Longmei [2 ]
Teklemariam, Takele [2 ]
Hantash, Basil M. [2 ,3 ]
机构：
[1] San Jose State Univ, San Jose, CA 95192 USA
[2] Escape Therapeut Inc, San Jose, CA 95138 USA
[3] Elixir Inst Regenerat Med, San Jose, CA 95138 USA
来源：
REGENERATIVE MEDICINE | 2014年 / 9卷 / 04期
关键词：
AMSC; BMSC; differentiation; growth kinetics; hESC-MSC; immunosuppression; UMBILICAL-CORD BLOOD; HUMAN BONE-MARROW; ADIPOSE-TISSUE; STROMAL CELLS; OSTEOGENIC DIFFERENTIATION; GENE-EXPRESSION; TRANSPLANTATION; DERIVATION; CULTURE; VIVO;
D O I：
10.2217/RME.14.13
中图分类号：
Q813 [细胞工程];
学科分类号：
摘要：
Aim: To enumerate and characterize mesenchymal stem cells (MSC) derived from human embryonic stem cells (hESC) for clinical application. Materials & methods: hESC were differentiated into hESC-MSC and characterized by the expression of surface markers using flow cytometry. hESC-MSC were evaluated with respect to growth kinetics, colony-forming potential, as well as osteogenic and adipogenic differentiation capacity. Immunosuppressive effects were assessed using peripheral blood mononuclear cell (PBMC) proliferation and cytotoxicity assays. Results: hESC-MSC showed similar morphology, and cell surface markers as adipose (AMSC) and bone marrow-derived MSC (BMSC). hESC-MSC exhibited a higher growth rate during early in vitro expansion and equivalent adipogenic and osteogenic differentiation and colony-forming potential as AMSC and BMSC. hESC-MSC demonstrated similar immunosuppressive effects as AMSC and BMSC. Conclusion: hESC-MSC were comparable to BMSC and AMSC and hence can be used as an alternative source of MSC for clinical applications.
引用
收藏
页码：453 / 465
页数：13
相关论文
共 44 条
[1]   Optimization of Parameters for a More Efficient Use of Adipose-Derived Stem Cells in Regenerative Medicine Therapies [J].
Aguena, Meire ;
Fanganiello, Roberto Dalto ;
Lorico Tissiani, Luiz Alexandre ;
Andre Ishiy, Felipe Augusto ;
Atique, Rodrigo ;
Alonso, Nivaldo ;
Passos-Bueno, Maria Rita .
STEM CELLS INTERNATIONAL, 2012, 2012
[2]   Osteogenic differentiation of noncultured immunoisolated bone marrow-derived CD105+ cells [J].
Aslan, Hadi ;
Zilberman, Yoram ;
Kandel, Leonid ;
Liebergall, Meir ;
Oskouian, Rod J. ;
Gazit, Dan ;
Gazit, Zulma .
STEM CELLS, 2006, 24 (07) :1728-1737
[3]   Human Embryonic Stem Cell-Derived Mesenchymal Stem Cells as Cellular Delivery Vehicles for Prodrug Gene Therapy of Glioblastoma [J].
Bak, Xiao Ying ;
Lam, Dang Hoang ;
Yang, Jingye ;
Ye, Kai ;
Wei, Esther Lee Xing ;
Lim, Sai Kiang ;
Wang, Shu .
HUMAN GENE THERAPY, 2011, 22 (11) :1365-1377
[4]   Comparison of proliferative and multilineage differentiation potential of human mesenchymal stem cells derived from umbilical cord and bone marrow [J].
Baksh, Dolores ;
Yao, Raphael ;
Tuan, Rocky S. .
STEM CELLS, 2007, 25 (06) :1384-1392
[5]  
Banas A, 2012, METHODS MOL BIOL, V826, P61, DOI 10.1007/978-1-61779-468-1_6
[6]   Comparison of Gene Expression in Human Embryonic Stem Cells, hESC-Derived Mesenchymal Stem Cells and Human Mesenchymal Stem Cells [J].
Barbet, Romain ;
Peiffer, Isabelle ;
Hatzfeld, Antoinette ;
Charbord, Pierre ;
Hatzfeld, Jacques A. .
STEM CELLS INTERNATIONAL, 2011, 2011
[7]   OSTEOGENIC DIFFERENTIATION OF MESENCHYMAL STEM CELLS IS REGULATED BY OSTEOCYTE AND OSTEOBLAST CELLS IN A SIMPLIFIED BONE NICHE [J].
Birmingham, E. ;
Niebur, G. L. ;
McHugh, P. E. ;
Shaw, G. ;
Barry, F. P. ;
McNamara, L. M. .
EUROPEAN CELLS & MATERIALS, 2012, 23 :13-27
[8]   Mesenchymal stem cells from human bone marrow or adipose tissue differently modulate mitogen-stimulated B-cell immunoglobulin production in vitro [J].
Bochev, Ivan ;
Elmadjian, Gabriel ;
Kyurkchiev, Dobroslav ;
Tzvetanov, Liubomir ;
Altankova, Iskra ;
Tivchev, Peter ;
Kyurkchiev, Stanimir .
CELL BIOLOGY INTERNATIONAL, 2008, 32 (04) :384-393
[9]   Markers for Characterization of Bone Marrow Multipotential Stromal Cells [J].
Boxall, Sally A. ;
Jones, Elena .
STEM CELLS INTERNATIONAL, 2012, 2012
[10]   Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study [J].
Connick, Peter ;
Kolappan, Madhan ;
Crawley, Charles ;
Webber, Daniel J. ;
Patani, Rickie ;
Michell, Andrew W. ;
Du, Ming-Qing ;
Luan, Shi-Lu ;
Altmann, Daniel R. ;
Thompson, Alan J. ;
Compston, Alastair ;
Scott, Michael A. ;
Miller, David H. ;
Chandran, Siddharthan .
LANCET NEUROLOGY, 2012, 11 (02) :150-156
12345